Jun 6, 2023
ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden.
A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk.
Mar 6, 2023
Pune start-up gets US patent for delivering drugs to site-specific organs
The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up.
Jan 15, 2023
AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients
Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis.
Aug 28, 2022
Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare
Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late.
Aug 9, 2022
Preventing Stage 4 Cancer: India’s Revolutionary Blood Test | Dr. Nirmal Raut
Leading oncologists discuss OncoDiscover, India's first indigenous CTC blood test. By detecting Circulating Tumor Cells post-treatment, this affordable "Made in India" innovation catches cancer relapse before it reaches incurable Stage 4, dramatically changing the landscape of cancer care.
Aug 9, 2022
Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi
Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations.
Jul 1, 2022
Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients
Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients.
Jun 7, 2022
ASCO 2022: A feasibility study of EMF (erlotinib+methotrexate+5-fluorouracil) regimen in recurrent HNSCC and role of CTCs in assessment of outcomes.
A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response.
Feb 18, 2022
Manuscript: Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors
Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research.
Jun 8, 2021
ASCO 2021: CTCs demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh.
A study in Bangladesh found CTCs in 64% of HNSCC patients with chronic tobacco history, suggesting CTCs as a screening tool for early cancer detection.
Apr 22, 2021
Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells
A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring.
Oct 10, 2020
Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head
and Neck Cancer
Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer.
Jul 15, 2020
ASCO 2020: Device for the enumeration and continuous removal of circulating tumor cells in improving
overall survival of epithelial cancer patients
The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival.
- Page 3